Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells

Authors: Soma Mandal, James R Davie

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

The sex hormone estrogen (E2) is pivotal to normal mammary gland growth and differentiation and in breast carcinogenesis. In this in silico study, we examined metabolic differences between ER(+)ve breast cancer cells during E2 deprivation.

Methods

Public repositories of SAGE and MA gene expression data generated from E2 deprived ER(+)ve breast cancer cell lines, MCF-7 and ZR75-1 were compared with normal breast tissue. We analyzed gene ontology (GO), enrichment, clustering, chromosome localization, and pathway profiles and performed multiple comparisons with cell lines and tumors with different ER status.

Results

In all GO terms, biological process (BP), molecular function (MF), and cellular component (CC), MCF-7 had higher gene utilization than ZR75-1. Various analyses showed a down-regulated immune function, an up-regulated protein (ZR75-1) and glucose metabolism (MCF-7). A greater percentage of 77 common genes localized to the q arm of all chromosomes, but in ZR75-1 chromosomes 11, 16, and 19 harbored more overexpressed genes. Despite differences in gene utilization (electron transport, proteasome, glycolysis/gluconeogenesis) and expression (ribosome) in both cells, there was an overall similarity of ZR75-1 with ER(-)ve cell lines and ER(+)ve/ER(-)ve breast tumors.

Conclusion

This study demonstrates integral metabolic differences may exist within the same cell subtype (luminal A) in representative ER(+)ve cell line models. Selectivity of gene and pathway usage for strategies such as energy requirement minimization, sugar utilization by ZR75-1 contrasted with MCF-7 cells, expressing genes whose protein products require ATP utilization. Such characteristics may impart aggressiveness to ZR75-1 and may be prognostic determinants of ER(+)ve breast tumors.
Appendix
Available only for authorised users
Literature
1.
Gruber CJ, Tschugguel W, Schneeberger C, Huber JC: Production and actions of estrogens. N Engl J Med. 2002, 346: 340-352. 10.1056/NEJMra000471.CrossRefPubMed
2.
De CA, Favoni RE: Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens. Trends Pharmacol Sci. 1997, 18: 245-251.CrossRef
3.
Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM: William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat. 1997, 44: 23-38. 10.1023/A:1005835428423.CrossRefPubMed
4.
Seth P, Krop I, Porter D, Polyak K: Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene. 2002, 21: 836-843. 10.1038/sj.onc.1205113.CrossRefPubMed
5.
Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K: Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003, 1: 362-375.PubMed
6.
Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, Baggerly K, Sahin A, Aldaz CM: Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics. 2005, 6: 37-10.1186/1471-2164-6-37.CrossRefPubMedPubMedCentral
7.
Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de JP, Oredsson S, Ringner M, Hoglund M, Borg A: High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer. 2007, 46: 543-558. 10.1002/gcc.20438.CrossRefPubMed
8.
9.
10.
Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM: Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res. 2000, 60: 5977-5983.PubMed
11.
Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004, 6: 17-32. 10.1016/j.ccr.2004.06.010.CrossRefPubMed
12.
Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. Science. 1995, 270: 484-487. 10.1126/science.270.5235.484.CrossRefPubMed
13.
Romualdi C, Bortoluzzi S, D'Alessi F, Danieli GA: IDEG6: a web tool for detection of differentially expressed genes in multiple tag sampling experiments. Physiol Genomics. 2003, 12: 159-162.CrossRefPubMed
14.
Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998, 95: 14863-14868. 10.1073/pnas.95.25.14863.CrossRefPubMedPubMedCentral
15.
Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4: 3-10.1186/gb-2003-4-5-p3.CrossRef
16.
Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR: GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet. 2002, 31: 19-20. 10.1038/ng0502-19.CrossRefPubMed
17.
Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR: MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol. 2003, 4: R7-10.1186/gb-2003-4-1-r7.CrossRefPubMedPubMedCentral
18.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005, 102: 15545-15550. 10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral
19.
Phillips KK, Welch DR, Miele ME, Lee JH, Wei LL, Weissman BE: Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. Cancer Res. 1996, 56: 1222-1227.PubMed
20.
Zhu Y, Wang A, Liu MC, Zwart A, Lee RY, Gallagher A, Wang Y, Miller WR, Dixon JM, Clarke R: Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. Int J Oncol. 2006, 29: 1581-1589.PubMed
21.
bd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004, 203: 661-671. 10.1002/path.1559.CrossRef
22.
Rubio SA, Martinez SE, Corona JS, Ruiz AP, Rincon AE, Lagunas IA, Camacho JG, Moguel MC: EcoRI polymorphism of the metastasis-suppressor gene NME1 in Mexican patients with breast cancer. Breast Cancer Res Treat. 2006, 96: 159-161. 10.1007/s10549-005-9072-0.CrossRefPubMed
23.
Mandal S, Curtis L, Pind M, Murphy LC, Watson PH: S100A7 (psoriasin) influences immune response genes in human breast cancer. Exp Cell Res. 2007, 313: 3016-3025. 10.1016/j.yexcr.2007.03.020.CrossRefPubMed
24.
Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M: Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer. 2006, 6: 245-10.1186/1471-2407-6-245.CrossRefPubMedPubMedCentral
25.
Hsu LC, Huang X, Seasholtz S, Potter DM, Gollin SM: Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines. Oncogene. 2006, 25: 5517-5526. 10.1038/sj.onc.1209563.CrossRefPubMed
26.
Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, Hansen B, Devilee P, Cornelisse CJ: At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes Cancer. 1994, 9: 101-107. 10.1002/gcc.2870090205.CrossRefPubMed
27.
Wennmalm K, Calza S, Ploner A, Hall P, Bjohle J, Klaar S, Smeds J, Pawitan Y, Bergh J: Gene expression in 16q is associated with survival and differs between Sorlie breast cancer subtypes. Genes Chromosomes Cancer. 2007, 46: 87-97. 10.1002/gcc.20392.CrossRefPubMed
28.
Chen J, Lindblom A: Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. Clin Genet. 2000, 57: 394-397. 10.1034/j.1399-0004.2000.570511.x.CrossRefPubMed
29.
Olayioye MA, Hoffmann P, Pomorski T, Armes J, Simpson RJ, Kemp BE, Lindeman GJ, Visvader JE: The phosphoprotein StarD10 is overexpressed in breast cancer and cooperates with ErbB receptors in cellular transformation. Cancer Res. 2004, 64: 3538-3544. 10.1158/0008-5472.CAN-03-3731.CrossRefPubMed
30.
31.
Cuesta R, Laroia G, Schneider RJ: Chaperone hsp27 inhibits translation during heat shock by binding eIF4G and facilitating dissociation of cap-initiation complexes. Genes Dev. 2000, 14: 1460-1470.PubMedPubMedCentral
32.
Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun. 2005, 337: 224-231. 10.1016/j.bbrc.2005.09.040.CrossRefPubMed
33.
Krone CA, Ely JT: Controlling hyperglycemia as an adjunct to cancer therapy. Integr Cancer Ther. 2005, 4: 25-31. 10.1177/1534735404274167.CrossRefPubMed
34.
Chevrollier A, Loiseau D, Chabi B, Renier G, Douay O, Malthiery Y, Stepien G: ANT2 isoform required for cancer cell glycolysis. J Bioenerg Biomembr. 2005, 37: 307-316. 10.1007/s10863-005-8642-5.CrossRefPubMed
35.
Henry JL, Coggin DL, King CR: High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2. Cancer Res. 1993, 53: 1403-1408.PubMed
36.
Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK: Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis. 2002, 23: 967-975. 10.1093/carcin/23.6.967.CrossRefPubMed
37.
Ren S, Smith MJ, Louro ID, Kie-Bell P, Bani MR, Wagner M, Zochodne B, Redden DT, Grizzle WE, Wang N, Smith DI, Herbst RA, Bardenheuer W, Opalka B, Schutte J, Trent JM, Ben-David Y, Ruppert JM: The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene. 2000, 19: 1419-1427. 10.1038/sj.onc.1203462.CrossRefPubMed
38.
Coux O, Tanaka K, Goldberg AL: Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996, 65: 801-847. 10.1146/annurev.bi.65.070196.004101.CrossRefPubMed
39.
Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson PH: Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res. 2004, 10: 8720-8727. 10.1158/1078-0432.CCR-04-1235.CrossRefPubMed
40.
Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, Okada F, Sato S, Shimbara N, Ichihara A: Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 1991, 51: 6677-6685.PubMed
41.
Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka S, Mizutani K, Shimizu K, Nagahama M, Ito K, Tanaka T, Tsunoda T: Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocr Relat Cancer. 2004, 11: 843-854. 10.1677/erc.1.00818.CrossRefPubMed
42.
Saeki Y, Sone T, A T, Yokosawa H: Identification of ubiquitin-like protein-binding subunits of the 26S proteasome. Biochem Biophys Res Commun. 2002, 296: 813-819. 10.1016/S0006-291X(02)02002-8.CrossRefPubMed
43.
Nishida H, Suzuki T, Ookawa H, Tomaru Y, Hayashizaki Y: Comparative analysis of expression of histone H2a genes in mouse. BMC Genomics. 2005, 6: 108-10.1186/1471-2164-6-108.CrossRefPubMedPubMedCentral
44.
Faast R, Thonglairoam V, Schulz TC, Beall J, Wells JR, Taylor H, Matthaei K, Rathjen PD, Tremethick DJ, Lyons I: Histone variant H2A.Z is required for early mammalian development. Curr Biol. 2001, 11: 1183-1187. 10.1016/S0960-9822(01)00329-3.CrossRefPubMed
45.
Dunn KL, Espino PS, Drobic B, He S, Davie JR: The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol. 2005, 83: 1-14. 10.1139/o04-121.CrossRefPubMed
46.
Surmacz E: Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia. 2000, 5: 95-105. 10.1023/A:1009523501499.CrossRefPubMed
47.
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995, 270: 1491-1494. 10.1126/science.270.5241.1491.CrossRefPubMed
48.
Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, Pignatelli M: Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology. 2002, 40: 536-546. 10.1046/j.1365-2559.2002.01392.x.CrossRefPubMed
49.
Dabbs DJ, Bhargava R, Chivukula M: Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol. 2007, 31: 427-437. 10.1097/01.pas.0000213386.63160.3f.CrossRefPubMed
50.
Kulka J, Tokes AM: Claudin expression in breast tumors. Hum Pathol. 2005, 36: 859-10.1016/j.humpath.2005.04.005.CrossRefPubMed
51.
Colegio OR, Van IC, Rahner C, Anderson JM: Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture. Am J Physiol Cell Physiol. 2003, 284: C1346-C1354.CrossRefPubMed
52.
Zhang H, Stephens LC, Kumar R: Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer2. Clin Cancer Res. 2006, 12: 1479-1486. 10.1158/1078-0432.CCR-05-1519.CrossRefPubMed
53.
Yu JC, Hsu HM, Chen ST, Hsu GC, Huang CS, Hou MF, Fu YP, Cheng TC, Wu PE, Shen CY: Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility. J Biomed Sci. 2006, 13: 419-432. 10.1007/s11373-006-9069-7.CrossRefPubMed
54.
Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A: Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma. Int J Cancer. 1993, 55: 926-930. 10.1002/ijc.2910550609.CrossRefPubMed
55.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
Metadata
Title
An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells
Authors
Soma Mandal
James R Davie
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-181

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data

Research article

Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study

Research article

Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study

Research article

Radiotherapy waiting times for women with breast cancer: a population-based cohort study

Research article

Platelet-derived growth factor receptor-β, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma

Research article

Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits